Seeyond Increases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Seeyond boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 3,753 shares of the company’s stock after acquiring an additional 17 shares during the quarter. Seeyond’s holdings in IDEXX Laboratories were worth $2,370,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Meridian Wealth Partners LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at $26,000. Parisi Gray Wealth Management bought a new stake in IDEXX Laboratories during the 2nd quarter valued at $27,000. Wagner Wealth Management LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at $29,000. TCI Wealth Advisors Inc. raised its holdings in IDEXX Laboratories by 34.0% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 71 shares of the company’s stock valued at $45,000 after buying an additional 18 shares during the last quarter. Finally, Newfound Research LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at $47,000. Institutional investors own 84.70% of the company’s stock.

In other news, SVP Kathy V. Turner sold 276 shares of the company’s stock in a transaction dated Friday, August 27th. The shares were sold at an average price of $678.00, for a total value of $187,128.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Giovani Twigge sold 11,421 shares of the stock in a transaction dated Wednesday, August 4th. The shares were sold at an average price of $700.35, for a total transaction of $7,998,697.35. The disclosure for this sale can be found here. Insiders sold a total of 26,886 shares of company stock worth $18,646,894 over the last ninety days. Insiders own 2.06% of the company’s stock.

IDXX has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price target on shares of IDEXX Laboratories from $550.00 to $610.00 and gave the company a “neutral” rating in a report on Tuesday, August 3rd. Guggenheim lowered shares of IDEXX Laboratories from a “buy” rating to a “neutral” rating in a report on Monday, July 12th. Barclays upped their price objective on shares of IDEXX Laboratories from $616.00 to $750.00 and gave the stock an “overweight” rating in a report on Monday, August 2nd. Finally, Credit Suisse Group upped their price objective on shares of IDEXX Laboratories from $735.00 to $770.00 and gave the stock an “outperform” rating in a report on Friday, August 13th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $643.80.

Shares of NASDAQ:IDXX traded up $11.39 during midday trading on Thursday, reaching $634.51. The company’s stock had a trading volume of 1,655 shares, compared to its average volume of 406,905. The firm has a 50 day moving average of $661.98 and a 200-day moving average of $609.70. The firm has a market capitalization of $53.98 billion, a P/E ratio of 74.27, a PEG ratio of 4.10 and a beta of 0.92. The company has a quick ratio of 1.17, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. IDEXX Laboratories, Inc. has a 12-month low of $414.68 and a 12-month high of $706.95.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Friday, July 30th. The company reported $2.34 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.33. The firm had revenue of $826.14 million for the quarter, compared to the consensus estimate of $794.64 million. IDEXX Laboratories had a net margin of 23.89% and a return on equity of 115.28%. The company’s revenue was up 29.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.72 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 8.35 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management.

See Also: Hold Rating

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.